Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

   Recruiting · Phase 1 · Dry Eye Syndrome

   NCT06977724 · AbbVie Inc. · 2 U.S. investigators

   $64,101research payments

2. A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

   Completed · Phase 1 · Healthy Participants

   NCT05981976 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

   $63,854research payments

3. Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

   Terminated · Not applicable · Acute Myocardial Infarction

   NCT04743245 · Zoll Circulation Inc · 5 U.S. investigators

   $63,428research payments

4. Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

   Active, not recruiting · Phase 2 · Heart Failure

   NCT06122779 · E.r. Squibb & Sons, L.l.c. · 24 U.S. investigators

   $63,007research payments

5. [Trial of device that is not approved or cleared by the U.S. FDA]

   Withheld

   NCT06797271 · Neurent Medical Limited · 0 U.S. investigators

   $63,001research payments

6. Universal Influenza A Vaccine in Healthy Adults

   Completed · Phase 1 · Human Influenza

   NCT05155319 · Emergent Biosolutions Inc. · 0 U.S. investigators

   $62,738research payments

7. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

   Completed · Phase 3 · Eosinophilic Esophagitis

   NCT03633617 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

   $62,414research payments

8. A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

   Recruiting · Phase 1, Phase 2 · Geographic Atrophy

   NCT07215234 · Genzyme Corporation · 2 U.S. investigators

   $61,692research payments

9. A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

   Recruiting · Phase 1 · Moderate to Severe Plaque Psoriasis

   NCT06888193 · UCB SA · 3 U.S. investigators

   $60,729research payments

10. A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

    Completed · Phase 2 · COVID-19

    NCT04634409 · Eli Lilly and Company · 2 U.S. investigators

    $60,675research payments

11. RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

    Recruiting · Pain

    NCT01719055 · Boston Scientific Corporation · 10 U.S. investigators

    $60,587research payments

12. Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

    Recruiting · Phase 3 · Complex Cardiovascular Surgery With Cardiopulmonary Bypass

    NCT07094087 · Csl Behring · 1 U.S. investigator

    $60,469research payments

13. Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

    Completed · Overactive Bladder

    NCT05067478 · Sumitomo Pharma America, Inc. · 15 U.S. investigators

    $60,143research payments

14. Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

    Recruiting · Phase 3 · Pneumococcal Immunization

    NCT07348692 · Sanofi Pasteur Inc. · 4 U.S. investigators

    $60,054research payments

15. Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

    Completed · Phase 4 · Rheumatoid Arthritis (RA)

    NCT02541955 · Mallinckrodt Hospital Products Inc. · 1 U.S. investigator

    $60,000research payments

16. Two Dose Levels of Privigen in Pediatric CIDP

    Recruiting · Phase 4 · Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    NCT03684018 · Csl Behring · 6 U.S. investigators

    $59,913research payments

17. Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

    Recruiting · Phase 1 · Recurrent or Refractory Solid Tumors

    NCT02013336 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $59,780research payments

18. Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

    Withdrawn · Bipolar Disorder

    NCT06328140 · Sumitomo Pharma Co., Ltd. · 1 U.S. investigator

    $59,719research payments

19. [Trial of device that is not approved or cleared by the U.S. FDA]

    Withheld

    NCT07135999 · AbbVie Inc. · 5 U.S. investigators

    $59,562research payments

20. A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

    Completed · Ulcerative Colitis (UC)

    NCT01848561 · AbbVie Inc. · 39 U.S. investigators

    $59,403research payments

21. Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

    Recruiting · Phase 3 · Juvenile Idiopathic Arthritis

    NCT05609630 · AbbVie Inc. · 5 U.S. investigators

    $58,980research payments

22. Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

    Recruiting · Phase 1, Phase 2 · Mantle Cell Lymphoma

    NCT06029309 · Beigene USA, Inc. · 1 U.S. investigator

    $58,344research payments

23. A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

    Recruiting · Phase 2 · Solid Tumors Harboring MET Amplification

    NCT07196644 · AbbVie Inc. · 2 U.S. investigators

    $58,203research payments

24. Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

    Active, not recruiting · Phase 3 · Hemophilia A

    NCT04644575 · Sanofi US Services Inc. · 8 U.S. investigators

    $58,115research payments

25. Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

    Completed · Phase 3 · Primary Pulmonary Hypertension

    NCT03399604 · Liquidia Technologies, Inc. · 7 U.S. investigators

    $58,113research payments

26. A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

    Completed · Phase 3 · Lymphoma, Non-Hodgkin

    NCT03575351 · Celgene Corporation · 2 U.S. investigators

    $57,544research payments

27. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Recruiting · Phase 3 · Gastric Cancer

    NCT06731478 · Daiichi Sankyo Inc. · 3 U.S. investigators

    $57,456research payments

28. Randomized Study of TransAeris® System in Cardiac Surgery Patients at Risk of Prolonged Mechanical Ventilation

    Status unknown · Not applicable · Ventilator Induced Diaphragm Dysfunction

    NCT04899856 · Synapse Biomedical Inc · 0 U.S. investigators

    $57,130research payments

29. 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

    Recruiting · Phase 4 · Prostatic Neoplasms

    NCT06706921 · Blue Earth Diagnostics · 1 U.S. investigator

    $56,831research payments

30. Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

    Completed · Phase 2 · Generalized Lipodystrophy

    NCT04159415 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $56,787research payments

31. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

    Active, not recruiting · Phase 3 · Progressive Pulmonary Fibrosis

    NCT06025578 · E.r. Squibb & Sons, L.l.c. · 22 U.S. investigators

    $56,540research payments

32. Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

    Completed · Phase 2 · Classical Hodgkin Lymphoma

    NCT04318080 · Beone Medicines Ltd. · 3 U.S. investigators

    $56,194research payments

33. Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

    Recruiting · Not applicable · COPD

    NCT07222410 · Fisher & Paykel Healthcare Limited · 2 U.S. investigators

    $56,134research payments

34. Persona IQ Cohort Study

    Active, not recruiting · Osteo Arthritis Knee

    NCT06089291 · Zimmer Biomet Holdings, Inc. · 4 U.S. investigators

    $55,990research payments

35. Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

    Active, not recruiting · Phase 2 · Multiple Sclerosis

    NCT04879628 · Sanofi US Services Inc. · 2 U.S. investigators

    $55,816research payments

36. A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

    Completed · Phase 3 · Glabellar Lines

    NCT05248893 · AbbVie Inc. · 2 U.S. investigators

    $55,153research payments

37. A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT05894928 · Eli Lilly and Company · 2 U.S. investigators

    $55,089research payments

38. Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

    Completed · Phase 3 · Crohn's Disease

    NCT04075825 · Takeda Pharmaceuticals U.S.A., Inc. · 11 U.S. investigators

    $55,013research payments

39. A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

    Recruiting · Phase 3 · Carcinoma, Transitional Cell

    NCT07218380 · Eli Lilly and Company · 1 U.S. investigator

    $55,000research payments

40. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

    Completed · Phase 3 · Healthy Volunteers (Meningococcal Infection)

    NCT03691610 · Sanofi Pasteur Inc. · 12 U.S. investigators

    $54,618research payments

41. Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

    Completed · Phase 2 · Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

    NCT05141006 · AbbVie Inc. · 12 U.S. investigators

    $54,472research payments

42. Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

    Recruiting · Phase 1 · Metastases

    NCT05195710 · Sirtex Medical Inc · 1 U.S. investigator

    $54,000research payments

43. Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

    Completed · Hemophilia

    NCT05904210 · Hema Biologics, LLC · 8 U.S. investigators

    $53,575research payments

44. Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

    Completed · Not applicable · Chronic Rhinitis

    NCT05591989 · Neurent Medical Limited · 0 U.S. investigators

    $53,513research payments

45. NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

    Recruiting · Phase 2 · Neuroblastoma

    NCT06450041 · United Therapeutics Corporation · 1 U.S. investigator

    $53,114research payments

46. A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

    Terminated · Esophageal Carcinoma

    NCT05780736 · E.r. Squibb & Sons, L.l.c. · 10 U.S. investigators

    $52,912research payments

47. Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

    Completed · Phase 2, Phase 3 · Hemophilia

    NCT03974113 · Genzyme Corporation · 3 U.S. investigators

    $52,352research payments

48. Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

    Completed · Phase 3 · Hepatitis C Virus (HCV)

    NCT04903626 · AbbVie Inc. · 7 U.S. investigators

    $52,327research payments

49. A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

    Completed · Phase 3 · Episodic Migraine

    NCT04686136 · AbbVie Inc. · 23 U.S. investigators

    $52,200research payments

50. A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

    Completed · Phase 1 · Chronic Heart Failure

    NCT05659264 · ModernaTX, Inc. · 3 U.S. investigators

    $52,068research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.